Keros Therapeutics Inc (KROS) |
|
58.62 3.37 (6.1%)
|
03-07 03:37 |
|
Open: |
56.65 |
Pre. Close: |
55.25 |
|
High:
|
58.86 |
Low:
|
51.485 |
|
Volume:
|
108,928 |
Market Cap:
|
1,359M |
|
|
|
|
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
58.911 - 59.326 |
59.326 - 59.649 |
|
Low:
|
50.795 - 51.189 |
51.189 - 51.495 |
|
Close:
|
58.044 - 58.727 |
58.727 - 59.257 |
|
Technical analysis |
as of: 2021-03-05 5:10:07 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 77.82  One year: 88.76 |
| Support: |
Support1: 51.49 Support2: 42.84 |
| Resistance: |
Resistance1: 66.63 Resistance2: 75.99 |
| Pivot: |
61.96 |
| Moving Average: |
MA(5): 58.15 MA(20): 63.38
MA(100): 65.50 MA(250): |
| MACD: |
MACD(12,26): -2.09 Signal(9): -1.48 |
| Stochastic oscillator: |
%K(14,3): 20.95 %D(3): 13.46 |
| RSI: |
RSI(14): 42.84 |
| 52-week: |
High: 88.80 Low: 20.10 Change(%): 191.9 |
| Average Vol(K): |
3-Month: 15279 10-Days: 10313 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.KROS has closed above bottom band by 25.8%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 05 Mar 2021
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference - GlobeNewswire
Tue, 02 Mar 2021
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference - Yahoo Finance
Wed, 17 Feb 2021
Feb 17, 2021 - Piper Jaffray & Co. Buys Shattuck Labs Inc, Aytu BioScience Inc, Eaton Vance Corp, Sells Sempra Energy, Brookfield Infrastructure Corp, Keros Therapeutics Inc - GuruFocus.com
Wed, 17 Feb 2021
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance
Fri, 22 Jan 2021
Keros Therapeutics: Very Expensive For A Company Still In Early Stages Of Development - Seeking Alpha
Mon, 21 Dec 2020
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index - GlobeNewswire
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
23 |
| Shares Float (M) |
8 |
|
% Held by Insiders
|
14.90 |
|
% Held by Institutions
|
77.63 |
|
Shares Short (K)
|
632 |
|
Shares Short P. Month (K)
|
464 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
-1443.76 |
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.318 |
|
Sales Per Share
|
0.108 |
|
EBITDA (p.s.)
|
-1.546 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-34 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
543.52 |
|
Price to Cash Flow
|
-39.50 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
